CN100515478C - 治疗经前期综合征的中药组合物 - Google Patents
治疗经前期综合征的中药组合物 Download PDFInfo
- Publication number
- CN100515478C CN100515478C CNB2004100012221A CN200410001222A CN100515478C CN 100515478 C CN100515478 C CN 100515478C CN B2004100012221 A CNB2004100012221 A CN B2004100012221A CN 200410001222 A CN200410001222 A CN 200410001222A CN 100515478 C CN100515478 C CN 100515478C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- blood
- rhizoma
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 148
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 19
- 230000003821 menstrual periods Effects 0.000 title description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 35
- 230000001105 regulatory effect Effects 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 230000017531 blood circulation Effects 0.000 claims abstract description 10
- 239000008280 blood Substances 0.000 claims description 51
- 210000004369 blood Anatomy 0.000 claims description 51
- 229940079593 drug Drugs 0.000 claims description 31
- 206010022998 Irritability Diseases 0.000 claims description 27
- 208000020401 Depressive disease Diseases 0.000 claims description 20
- 208000024714 major depressive disease Diseases 0.000 claims description 20
- 201000003995 melancholia Diseases 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 9
- 230000003001 depressive effect Effects 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 241000208340 Araliaceae Species 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000008187 granular material Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 230000035568 catharsis Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 240000004371 Panax ginseng Species 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000011552 rat model Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102400000050 Oxytocin Human genes 0.000 description 7
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 7
- 101800000989 Oxytocin Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 7
- 229960001723 oxytocin Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000008451 emotion Effects 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000019790 abdominal distention Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000000583 progesterone congener Substances 0.000 description 4
- 208000027140 splenic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 240000004859 Gamochaeta purpurea Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- -1 aliphatic alcohols Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000009752 danzhi xiaoyao Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 241001571352 Amomum longiligulare Species 0.000 description 1
- 244000141331 Amomum villosum Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241000213015 Bupleurum scorzonerifolium Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000963421 Curcuma kwangsiensis Species 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 1
- 244000075634 Cyperus rotundus Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100012221A CN100515478C (zh) | 2004-01-02 | 2004-01-02 | 治疗经前期综合征的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100012221A CN100515478C (zh) | 2004-01-02 | 2004-01-02 | 治疗经前期综合征的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1640436A CN1640436A (zh) | 2005-07-20 |
CN100515478C true CN100515478C (zh) | 2009-07-22 |
Family
ID=34867067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100012221A Expired - Lifetime CN100515478C (zh) | 2004-01-02 | 2004-01-02 | 治疗经前期综合征的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100515478C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101254261B (zh) * | 2008-03-25 | 2013-06-26 | 深圳力瑞医药科技有限公司 | 一种具有催眠、抗抑郁、抗焦虑作用的药物组合物及其制备方法 |
KR102262306B1 (ko) * | 2013-07-04 | 2021-06-09 | (주)아모레퍼시픽 | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 |
CN104524479B (zh) * | 2015-01-27 | 2018-05-25 | 葛彦欣 | 一种治疗经前期综合征的中药组合物及其制备方法 |
CN105106436A (zh) * | 2015-10-10 | 2015-12-02 | 裴捍东 | 一种防治郁证的中药养生茶 |
CN116585438B (zh) * | 2023-06-28 | 2024-01-02 | 秦皇岛市山海关药业有限责任公司 | 经前舒颗粒在制备治疗更年期综合征的产品中的应用 |
CN116808125A (zh) * | 2023-07-07 | 2023-09-29 | 东南大学 | 一种抗抑郁的中药组合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1203805A (zh) * | 1998-06-04 | 1999-01-06 | 李胤良 | 防治月经病证保健饮料 |
-
2004
- 2004-01-02 CN CNB2004100012221A patent/CN100515478C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1203805A (zh) * | 1998-06-04 | 1999-01-06 | 李胤良 | 防治月经病证保健饮料 |
Also Published As
Publication number | Publication date |
---|---|
CN1640436A (zh) | 2005-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN101513437B (zh) | 一种抗疲劳中药组合物及其制备方法 | |
CN102178867B (zh) | 一种益气健脾补肾的中药方剂及其制品 | |
CN1679913A (zh) | 治疗妇科疾病的妇科再造胶囊 | |
CN103301440B (zh) | 一种能够温阳补肾的中药 | |
CN104998063A (zh) | 一种抗疲劳的药物制剂 | |
CN101953918B (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN115487239A (zh) | 一种治疗失眠伴焦虑抑郁的药物组合物及其制备方法 | |
CN100515478C (zh) | 治疗经前期综合征的中药组合物 | |
CN1330345C (zh) | 一种治疗高血脂症的中药组合物及其制备方法 | |
CN100528220C (zh) | 舒肝清热、健脾养血的妇科中成药及其制备方法 | |
CN105267559B (zh) | 一种治疗糖尿病周围神经病变的药物及其制作方法 | |
CN106492138A (zh) | 治疗失眠的中药制剂 | |
CN105796845A (zh) | 药物组合物在制备治疗女性更年期综合征药物中的用途 | |
CN104189764A (zh) | 一种治疗介入术后发热的中药制剂及其制备方法 | |
CN1985982B (zh) | 一种治疗结肠炎的药物及其制备方法 | |
CN106581236A (zh) | 一种促进胃动力的药物组合物及其制备方法和应用 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN105412424A (zh) | 一种含有艾叶的润肠通便的药物制剂及其制备方法 | |
CN105664102A (zh) | 一种用于提高免疫力的中药组合物 | |
CN101278982A (zh) | 治疗急慢性乙型肝炎的复方中药制剂及其制备方法 | |
CN101647901B (zh) | 治疗妇女产后之气血亏虚症的口服中药制剂及其生产方法 | |
CN104162090B (zh) | 一种药物组合物及其制备方法 | |
CN104056234A (zh) | 一种解酒的药物及其制备方法 | |
CN103977154A (zh) | 一种用于保肝护肝的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: QINHUANGDAO SHANHAIGUAN PHARMACEUTICAL FACTORY Free format text: FORMER OWNER: QIHUANG PHARMACEUTICAL INVESTMENT + RESEARCH CO., LTD. Effective date: 20060106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060106 Address after: 066200 Qinhuangdao City, Hebei Province east of Shanhaiguan camp Applicant after: SHANHAIGUAN PHARMACEUTICAL FAC Address before: 100026, four floor, building 13, East Lane, Bai Jia Zhuang, Beijing, Chaoyang District Applicant before: QIHUANG PHARMACEUTICAL INVEST |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: QINHUANGDAO SHANHAIGUAN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANHAIGUAN PHARMACEUTICAL FACTORY, QINHUANGDAO CITY |
|
CP03 | Change of name, title or address |
Address after: 066200 Qinhuangdao City, Hebei Province town of Shanhaiguan District Road No. 126 Patentee after: QINHUANGDAO SHANHAIGUAN PHARMACEUTICAL Co.,Ltd. Address before: 066200 Qinhuangdao City, Hebei Province east of Shanhaiguan camp Patentee before: SHANHAIGUAN PHARMACEUTICAL FAC |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090722 |